Results 141 to 150 of about 12,467 (245)

Beyond CFTR: Ivacaftor's role in restoring cellular redox balance and preventing ferroptosis. [PDF]

Redox Biol
Rubin M, Artusi I, Rossetto M, Gucciardi A, Di Paolo ML, Bosello Travain V, Zeppilli D, Orian L, Miotto G, Friedmann Angeli JP, Cozza G.   +10 more
europepmc   +1 more source

Comparative efficacy and safety of CFTR modulators for people with cystic fibrosis with phe508del mutation: a systematic review and bayesian network meta-analysis. [PDF]

EClinicalMedicine
Safeer V S M, Behl S, Vaidya PC, Tiwari P, Bharti SK, Nahan N, Kumar Sahu J, Bansal D.   +7 more
europepmc   +1 more source

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation

, 2018
Kerstin Pohl, David P. Nichols, Jennifer L. Taylor‐Cousar, Milene T. Saavedra, Matthew Strand, Jerry A. Nick, Preston E. Bratcher   +6 more
openalex   +2 more sources

CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis. [PDF]

Cells
Lo Cicero S, Castelli G, Ceci A, Cerio AM, Blaconà G, Virgulti M, Allushi S, Sette G, Spadaro F, Amato F, Melotti P, Sorio C, Cimino G, Biffoni M, Lucarelli M, Eramo A.   +15 more
europepmc   +1 more source

Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. [PDF]

BMJ Open Respir Res
Evans IES, Smith D, Henderson D, Riddles T, Masel P, Moore V, Burke AJ, Thomson RM, Reid DW.   +8 more
europepmc   +1 more source

People with cystic fibrosis with high sputum neutrophil elastase on elexacaftor-tezacaftor-ivacaftor exhibit worse pulmonary function and pro-inflammatory airway milieu. [PDF]

Sci Rep
Cammarata-Mouchtouris A, Giraldo DM, Collins GL, Parrilla MM, Kim SO, Mansour S, Giacalone VD, Cottrill KA, Tirouvanziam R, Chandler JD.   +9 more
europepmc   +1 more source

301 Multi-center study exploring the impact of co-adherence to inhaled therapies on forced expiratory volume in 1 second response in people with cystic fibrosis taking elexacaftor/tezacaftor/ivacaftor in the CFHealthHub Learning Health System

, 2022
T. Daniels, L. Lai, Z. Hoo
openalex   +1 more source

ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis [PDF]

, 2020

openalex   +1 more source

Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis [PDF]

Ryan Marsh, Claudio Dos Santos, Alexander Yule, Neele Dellschaft, Caroline L. Hoad, Christabella Ng, Giles Major, Alan R Smyth, Damian Rivett, Chris Gast   +9 more
openalex   +2 more sources

Highly Effective Modulator Therapy in Cystic Fibrosis: Addressing Unusual Variants in the Middle East. [PDF]

Pulm Med
Isse S, Wahla AS, Uzbeck MH, Zoumot Z, Abuzakouk M, Shafiq I.   +5 more
europepmc   +1 more source